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Abstract
Rationale: Multiple myeloma (MM) is a multifocal malignancy of bone marrow plasma cells, characterized by
vicious cycles of remission and relapse that eventually culminate in death. The disease remains mostly incurable
largely due to the complex interactions between the bone microenvironment (BME) and MM cells (MMC). In
the “vicious cycle” of bone disease, abnormal activation of osteoclasts (OCs) by MMC causes severe osteolysis,
promotes immune evasion, and stimulates the growth of MMC. Disrupting these cancer-stroma interactions
would enhance treatment response.
Methods: To disrupt this cycle, we orthogonally targeted nanomicelles (NM) loaded with non-therapeutic
doses of a photosensitizer, titanocene (TC), to VLA-4 (α4ß1, CD49d/CD29) expressing MMC (MM1.S) and
αvß3 (CD51/CD61) expressing OC. Concurrently, a non-lethal dose of a radiopharmaceutical,
18F-fluorodeoxyglucose ([18F]FDG) administered systemically interacted with TC (radionuclide stimulated
therapy, RaST) to generate cytotoxic reactive oxygen species (ROS). The in vitro and in vivo effects of RaST were
characterized in MM1.S cell line, as well as in xenograft and isograft MM animal models.
Results: Our data revealed that RaST induced non-enzymatic hydroperoxidation of cellular lipids culminating
in mitochondrial dysfunction, DNA fragmentation, and caspase-dependent apoptosis of MMC using VLA-4 avid
TC-NMs. RaST upregulated the expression of BAX, Bcl-2, and p53, highlighting the induction of apoptosis via
the BAK-independent pathway. The enhancement of multicopper oxidase enzyme F5 expression, which inhibits
lipid hydroperoxidation and Fenton reaction, was not sufficient to overcome RaST-induced increase in the
accumulation of irreversible function-perturbing α,ß-aldehydes that exerted significant and long-lasting damage
to both DNA and proteins. In vivo, either VLA-4-TC-NM or αvß3-TC-NMs RaST induced a significant
therapeutic effect on immunocompromised but not immunocompetent MM-bearing mouse models. Combined
treatment with both VLA-4-TC-NM and αvß3-TC-NMs synergistically inhibited osteolysis, reduced tumor
burden, and prevented rapid relapse in both in vivo models of MM.
Conclusions: By targeting MM and bone cells simultaneously, combination RaST suppressed MM disease
progression through a multi-prong action on the vicious cycle of bone cancer. Instead of using the standard
multidrug approach, our work reveals a unique photophysical treatment paradigm that uses nontoxic doses of
a single light-sensitive drug directed orthogonally to cancer and bone cells, followed by radionuclide-stimulated
generation of ROS to inhibit tumor progression and minimize osteolysis in both immunocompetent murine and
immunocompromised human MM models.
Key words: multiple myeloma, bone marrow, tumor microenvironment, orthogonal drug delivery, nanomicelles,
photosensitizer, Cerenkov radiation
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Introduction
MM is neoplasia of plasma cells in the bone
marrow and is the second most common
hematological malignancy [1-7]. Clinically, the disease
progresses
from
asymptomatic
monoclonal
gammopathy of undetermined significance (MGUS)
and smoldering multiple myeloma (SMM) to an
increase in the number of malignant plasma cells and
the appearance of CRAB symptoms (hypercalcemia,
renal failure, anemia, and bone lesions) [8-10]. At the
pathogenetic level, several mutations can contribute
to the clonal expansion of malignant plasma cells [7].
However, advanced MM and MGUS are often
indistinguishable in the load and type of karyotypic
and sequence abnormalities [11], suggesting a key role
of MM cell-extrinsic factors in determining
tumorigenic progression of bone lesions [12-15].
Indeed, several lines of evidence show that some
pro-MM changes in BME accompany, or even
precede, the appearance of bone lesions [16-19].
Bone marrow (BM), the primary anatomical site
of hematopoiesis [1, 20-22], comprises diverse cell
populations [23]. Particularly, hematopoietic cells
localized in the BM interact extensively with the bone
marrow stromal cells (BMSC) and cells that regulate
bone morphology, including matrix-deposing
osteocytes and osteoblasts of mesenchymal origin and
bone-resorption osteoclasts (OCs) of myeloid lineage
[24]. Together with the extracellular matrix proteins
(ECM) [25-28], bone resident cells interact with MM
cells to promote tumor growth, survival, immune
suppression, and resistance to chemotherapy [17, 19,
29-31]. These complex interactions result in osteolytic
lesions, which occur in 90% of MM patients [32] with
a high rate of skeletal-related events that affect
morbidity, quality of life, and survival [33].
The extensive heterogeneity and high frequency
of MM relapse require autologous stem cell
transplantation for eligible patients and the
administration of combination drugs that include
immunomodulatory
drugs
(thalidomide,
lenalidomide,
pomalidomide),
corticosteroids
(dexamethasone), proteasome inhibitors (bortezomib,
carfilzomib,
ixazomib),
deacetylase
inhibitors
(panobinostat),
and
monoclonal
antibodies
(Elotuzumab, Daratumumab) [34-42]. To prevent or
minimize severe skeletal-related events, current
therapies include inhibitors of bone resorption
(zoledronic acid, pamidronates, denosumab) and
radiation [32]. These interventions are used at
sufficiently high doses to exert a therapeutic effect but
also induce dose-limiting side effects. A strategy to
overcome this challenge is to use sub-lethal doses of
drugs and selectively enhance therapeutic effect in the
target cells.
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MM and the BME provide a rich source of
biomarkers for targeting diverse cells, including
CD38, CS1, VLA-4, and αvß3 proteins. Previously, we
demonstrated that VLA-4 integrin is upregulated on
MM cells and MM protective lymphocytes and
macrophages [43], thus constituting a useful
therapeutic target. To minimize organ and systemic
toxicity, we developed a new treatment paradigm
called Cerenkov radiation-induced therapy where
light-sensitive drugs (photosensitizers) can absorb
Cerenkov radiation from radiopharmaceuticals [42,
43] to generate cytotoxic ROS. We recently coined the
term radionuclide stimulated therapy (RaST) to
account for other potential contributing factors to the
observed therapeutic effects other than Cerenkov
radiation [44]. The ability of RaST to induce
therapeutic effect only when the two components
co-localize in the same or adjacent cells enables us to
administer nontoxic amounts of both photosensitizers
and radiopharmaceuticals to effect precision therapy.
Using contact-facilitated drug delivery strategy [45,
46], we recently demonstrated the high loading
capacity and delivery of unmodified photosensitizers
in NMs targeted to tumors [43]. Compared to large
nanoparticles with limited diffusivity [47-49], the
small size of the NMs (20 nm) facilitates the
penetration and distribution in the highly
vascularized and compartmentalized bone marrow
where MM resides [50]. Despite the improvement in
therapeutic response, the rate of MM relapse
remained high, probably caused by either
cell-intrinsic adaptations or protective interactions
with the bone niche. Previous studies established that
increased
osteoclastogenesis
and
subsequent
osteolytic activity are essential for MM survival [6,
51]. OC differentiation and activity promote MM
progression and relapse by stimulating proliferation
and reactivation from dormancy of MMC [52]. The
integrin αvß3, which is over-expressed on these cells
but not in MM cells, plays a vital role in the osteolytic
function of OCs [53, 54]. A unique benefit of RaST is
that the photophysical ROS-generating mechanism is
applicable in any targeted cell type, favoring the use
of the same light-sensitive drug delivered
orthogonally to targeted cells to achieve disparate
multicellular therapy.
In this study, we harnessed the orthogonal
expression of VLA-4 on the cell surface of MM [55,
56], and αvß3 on the plasma membrane of OCs [57,
58], as well as the expression of GLUT1 (CD71)
glucose transporter on both cell types [59-62] for a
new intercellular RaST. Incorporation of the
photosensitizer, TC, into NMs (20 nm) targeted to
either αvß3 or VLA-4 allowed us to deliver TC
selectively to OC and MM cells, respectively. Using
http://www.thno.org
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[18F]FDG to initiate ROS generation, we elucidated the
mechanism of RaST-induced cell death (Figure 1). Our
results point to a paradigm where the direct depletion
of pro-tumorigenic cells in the BME combines with a
multidimensional cell death mechanism to achieve a
sustainable therapeutic effect in a disease that
currently remains incurable. By using the same drug
to treat both cell types, we mitigated the cumulative
toxic effects of multidrug therapy on healthy tissue. A
requirement for treating MM patients with relapsed
disease is to add at least a drug from a non-refractory
group. With many pharmacologic drugs unable to
meet this threshold, multicellular RaST is a potential
standalone therapy or a component of multidrug
therapy of MM and other bone lesions.

Methods
Cell lines and reagents
MM1.S human MM [63] and 5TGM1 murine MM
[64] cell lines, either naïve or carrying Click Beetle Red
(CBR) luciferase and Green Fluorescent Protein (GFP)
reporters (MM1.S/CBR/GFP and 5TGM/CBR/GFP,
respectively), as well as MM1.S/CBR/GFP resistant
to RaST and MM1.S/CBR/GFP without CD49d, were
generously provided by Dr. DiPersio (Washington
University School of Medicine, WUSM, St. Louis).
Cells were routinely cultured in complete medium
(CM) consisting of Iscove’s Modified Dulbecco’s
Media (Thermo Fisher Scientific, Waltham, MA)
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supplemented with 10% heat-inactivated fetal bovine
serum (FBS, ThermoFisher Scientific, Waltham, MA)
and 50 µg/mL Gentamycin (Thermo Fisher Scientific,
Waltham, MA). The cells were routinely washed in
phosphate-buffered saline (PBS, Thermo Fisher
Scientific, Waltham, MA), pH 7.4. VLA-4 and αvß3
targeted
NM
were
loaded
with
TC
(Bis(cyclopentadienyl)titanium(IV)
dichloride,
Sigma-Aldrich, St. Louis, MO) [43, 46]. Protein content
was routinely measured with PierceTM bicinchoninic
acid (BCA) assay (Thermo Fisher Scientific Waltham,
MA).

Synthesis of VLA4-PEG2000-PE
A VLA-4 antagonist based on the highly
selective LLP2A [65] peptidomimetic, which binds
selectively to activated α4ß1 heterodimers [65] was
synthesized and coupled to polyethylene glycol–
phosphatidyethanolamine anchor. Briefly, rink amide
4-methylbenzhydrylamine resin (MBHA) resin was
fluorenylmethyloxycarbonyl
chloride
(Fmoc)
deprotected with 20% piperidine in dimethylformamide (DMF). Fmoc-Ach-OH dissolved in
hydroxy-benzotriazole (HOBt) and 1,3-diisopropylcarbodiimide (DIC) in DMF was coupled at RT for 2 h.
The Fmoc deprotection with 20% piperidine, and
serial coupling and deprotection cycles with
Fmoc-Aad(tBu) and Fmoc- Lys(Dde) were performed.
After removal of Fmoc, a solution of 2-(4-(3-otolylureido)phenyl)acetic acid, HOBt and DIC in DMF

Figure 1. Schematic illustration of orthogonal RaST. NMs are loaded with a light-sensitive drug, TC, but directed to different cells that express VLA-4 (MM) and αvß3
(OCs) in the BM. The expression of GLUT1 on both MM and OCs provides additional selectivity for eradicating only cells that express GLUT1 and either VLA-4 or αvß3.

http://www.thno.org
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was added overnight, washed, and the Dde protecting
group removed with 2% hydrazine in DMF. A
solution of trans-3-(3-pyridyl) acrylic acid, HOBt and
DIC in DMF was added and coupling was ensured via
a negative Kaiser test. The crude product was cleaved
with 95% trifluoroacetate (TFA): 2.5% water: 2.5%
triisopropylsilane, precipitated with diethyl ether and
purified using RP-HPLC. VLA-4 ligand dissolved in
ethanol was mixed with 2-iminothiolane in methanol
and allowed to react for 2 h @ 25 ºC. N-(4-(Pmaleimidophenyl) butyrl)-phosphatidylethanolamine
(MPB-PEG2000-DSPE) was added and incubated for 2
h. The purified lyophilized sample was a white solid
(VLA-4-PEG-PE, Calculated, 3781; Observed, m/z.
3780).

Synthesis of αvß3-integrin antagonist
The αvß3-integrin antagonist was a quinalone
nonpeptide developed by Bristol-Myers Squibb
Medical Imaging (US patent 6,511,648 and related
patents), which was initially reported and
characterized as the 111In-DOTA conjugate RP478 and
cyan 5.5 homologue TA145 [66]. The specificity of the
αvß3 ligand mirrors that of LM609 and has a 15-fold
preference for the Mn2+ activated receptor (21 nM)
[67]. The IC50 estimates for αvß5, α5ß1 and GP IIbIIIa
were > 10 µM (BMSMI, Billerica, MA, USA, US patent
6,511,648 and related patents). The antagonist amide
coupled to PEG2000-phosphatidylethanolamine (αvß3PEG-PE) was a gift from Kereos, Inc., St. Louis, MO.
(Calculated: 4021, Observed: m/z 4020).

Synthesis of VLA-4-TC-NM and αvß3-TC-NM
Targeted titanocene nanomicelles were prepared
as previously described [43]. Briefly, phospholipid/
polysorbate 80 micelles were prepared as a
microfluidized suspension comprised of 20%
polysorbate tween 80 (v/v) (NOF America, White
Plains, NY), a 2.0% (w/v) surfactant commixture, and
1.7% (w/v) glycerin in filtered MilliQ Nanopure
water. The surfactant commixture included 0 or 2
mole% titanocene dichloride (TiCl2, Sigma-Aldrich,
St. Louis, MO) and 0 or 0.15 mole% of a
VLA4-PEG-PE or αvβ3-PEG-PE with the remainder
phosphatidylcholine (>98% purity, NOF America,
White Plains, NY). The surfactant components were
dried from organic solvent into a film, resuspended in
nanopure water, and combined with polysorbate 80,
buffer, Nanopure water, and glycerin. The mixture
was sonicated at 4 °C for 3 min, then microfluidized
(LV1, Microfluidics, Westwood, MA) at 20,000 psi for
5 passes. Dynamic light scattering (DLS)
physicochemical characteristics (nominal of 10
estimates) of the αvß3-NM were: particle size: 18 ± 2
nm, polydispersity: 0.2 ± 0.02, zeta potential 1.4 ± 0.6
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mV and for the VLA-4-NM were: particle size: 20 ± 1.4
nm, polydispersity: 0.3 ± 0.01, zeta potential: -0.3± 0.2
mV. The NM were filtered with 0.2 µm filter into
sterile serum vials, preserved under inert gas, capped
and crimp-sealed, then stored at 4 °C until use.
Further data schematically illustrating the NM and
TEM, as well as the titanocene NM pharmacokinetic
and biodistribution were previously described [43].

[18F]FDG production
[18F]FDG was produced with an average specific
activity 70-299 mCi/mL by the Mallinckrodt Institute
of Radiology’s Cyclotron Facility and Nuclear
Pharmacy at Washington University School of
Medicine in compliance with current good
manufacturing practices.

Murine osteoclast differentiation
Bone marrow macrophages (BMM) were
isolated and induced to differentiate into OCs
according to previously methodology [68], with
modifications.
Fox
Chase
SCID
beige
or
C57BL/6-KaLwRij male mice (5-7 weeks old) were
euthanized, and femurs and tibiae were aseptically
dissected. Both ends of bones were removed, and
bone marrow was extracted using centrifugation at
10,000 × g for 10 s. The pellet was suspended in
Roswell Park Memorial Institute 1640 medium
(RPMI-1640) supplemented with 10% heat-inactivated
HyClone defined Fetal Bovine Serum (Thermo Fisher
Scientific, Waltham, MA) and 50 µg/mL Gentamicin
(RPMI-10G) containing 5 × 10-6 mg/mL recombinant
mouse M-CSF (R&D Systems, Minneapolis, MN) and
plated on 10 cm Petri dishes (Valmark, Thomas
Scientific, Swedesboro, NJ). The plating density of
BMM from 2 mice for each plate was routinely
maintained. The plates were incubated overnight at 37
°C and humidified 5% CO2 atmosphere. The
non-adherent cells were harvested, washed once with
RPMI-10G, and plated on 24-well tissue culture plates
(TPP, Midwest Scientific, Valley Park, MO) at 4 × 105
cells per well in RPMI-10G supplemented with 100
ng/mL RANKL (R&D Systems, Minneapolis, MN).
The medium was renewed every 72 h for a minimum
of seven days.

Cell viability
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)
assay, a colorimetric assay for assessing cell viability,
was performed using CellTiter 96® Aqueous One
Solution Cell Proliferation Reagent (Promega,
Madison, MI). After treatment, the CM was carefully
removed from each well and replaced with 0.5 mL of
PBS containing 50 µL tetrazolium compound
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carbooxymethoxyp
http://www.thno.org
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henyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt;
MTS) and phenazine ethosulfate (PES, electron
coupling reagent) (CellTiter 96® Aqueous One
Solution Cell Proliferation Reagent, Promega,
Madison, WI) to determine the percentage of live
cells. The plates were incubated at 37 °C for 1-4 h to
allow the tetrazolium compound to develop. The
resulting absorbance was detected at 490 nm with a
Synergy/NEO2
multi-mode
reader
(BioTek,
Winooski, VT).

In vitro RaST
In vitro RaST experiments were performed in 24
well plates containing 4 x 105 cells per well in 1 mL of
CM. The treatment was initiated by the addition of
either VLA-4-TC-NM (5 µL per well, 0.5 µg TC) or
αvß3-TC-NM (5 µL per well, 0.5 µg TC), or their
combination. The NM were allowed to bind to target
receptors at 4 °C for 1 h. The medium with unbound
NM was carefully removed and replaced with 1 mL
fresh medium. At this time, 3.7 MBq/mL (0.1 mCi)
[18F]FDG in saline was added to the appropriate wells,
and the plates were placed in the 37 °C/5% CO2
humidified atmosphere for the indicated amounts of
time. After the completion of treatment, the medium
was carefully removed and 0.5 mL of PBS containing
50 µL MTS reagent (CellTiter 96® Aqueous One
Solution Cell Proliferation Reagent, Promega,
Madison, WI) was added to each well to determine
the percentage of live cells. The plates were incubated
at 37 °C for 1-4 h to allow the tetrazolium compound
to be reduced to form formazan dye. The resulting
absorbance was detected at 490 nm with a
Synergy/NEO2
multi-mode
reader
(BioTek,
Winooski, VT). The data were reported as a percent of
live cells compared to the untreated cells (100%).

Reactive oxygen species assay
TC is a photosensitizer and is known to generate
ROS upon irradiation by UV light or Cerenkov
radiation [69, 70]. ROS measurements were carried
out at RT using 2’,7’-dichlorodihydrofluorescein
diacetate (H2DCFDA, Thermo Fisher Scientific,
Waltham, MA) as ROS indicator. RaST treatments
were performed as described in the in vitro RaST
section. After the VLA-4-TC-NM RaST and the
controls were added to the appropriate wells,
H2DCFDA was added to each well as follows.
H2DCFDA was reconstituted in DMSO immediately
prior to being added to each well at 5 µM final
concentration and the plates were incubated in
humidified atmosphere at 37 °C/5% CO2 for 72 h. At
the end of the incubation period, the dye was excited
at 495 nm and the emitted fluorescence was detected
at 520 nm with a Synergy/NEO2 multi-mode reader
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(BioTek, Winooski, VT). The cells were mechanically
harvested with a rubber-tipped cell scraper (Sarstedt,
Newton, NC), washed twice with PBS, lysed with 200
µL RIPA buffer at 4 °C for 30 min and the total protein
content was determined with the BCA assay. The data
were reported as fluorescence intensity per µg of
protein.

Oxidative stress markers profile
Three oxidative stress markers were included in
the matabolomic analysis of MM1.S cells: 3β,5α,6βtrihydroxycholestane
(triol,
CAS
1253-84-5),
7-ketocholesterol
(CAS
566-28-9),
and
malondialdehyde (MDA, CAS 542-78-9). To
investigate the oxidative stress markers resulting from
RaST, the cells were treated with VLA-4-TC-NM RaST
or left untreated as in the in vitro RaST section. At the
end of treatment, the cells were mechanically
harvested with a rubber-tipped cell scraper (Sarstedt,
Newton, NC) and washed twice with PBS. The
cultured cell samples were lysed with 200 μL of 4:1
MeOH/Water, containing 10 ng each of deuterated
triol-d7, deuterated 7-ketocholesterol-d7, deuterated
4-hydroxy nonenal-d3 (4-HNE-d3), and deuterated
4-hydroxy hexenal-d3 (4-HHE-d3) as internal
standards. An aliquot (50 μL) of the cell lysate was
dried under a stream of nitrogen. The sterol markers
were derivatized with dimethylglycine (DMG), while
the aldehyde markers in the second aliquot (50 μL)
were derivatized with O-benzylhydroxylamine to
improve MS sensitivity as well as chromatographic
properties. The analysis was performed using a
Shimadzu 20AD HPLC system coupled to a tandem
mass spectrometer (API-6500+Qtrap: Applied
Biosystems, Waltham, MS) operated in multiple
reaction monitoring mode (MRMM). The positive ion
spray ionization mode (ESIM) was used for detection
of analytes and the internal standards. The samples
were injected in triplicate for data averaging. Data
processing was conducted with Analyst 1.6.3 software
(Applied Biosystems, Waltham, MS). For each
analyte, the peak area was calculated and compared
to the peak area of the corresponding internal
standard. The resulting ratios for each analyte were
reported as relative abundance.

Lipid hydroperoxide assay
Lipid hydroperoxide measurements were
performed using the lipid hydroperoxide test
(Northwest Life Sciences Specialties, LLC, Vancouver,
WA). Intracellular lipid peroxides oxidize ferrous iron
(Fe2+) to form ferric iron (Fe3+). The amount of Fe3+
reflects the lipid peroxide content and is detected by
its reaction with 3,3’-Bis[N,N-bis(carboxymethyl)aminomethyl]-o-cresolsulonephtalein
(Xylenol
http://www.thno.org
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Orange). MM1.S cells were either treated with
VLA-4-TC-NM RaST, VLA-4-TC-NM alone, [18F]FDG
alone or left untreated for 72 h. The cells were then
mechanically harvested, lysed, 10 µL lysate aliquots
from each well were reserved for the protein content
measurement, and treated with catalase to inactivate
endogenous H2O2. The lysates were reacted with the
ferrous iron reagent. The resulting Fe3+ was detected
with Xylenol Orange as a chromogen at 560 nm using
Synergy/NEO2
multi-mode
reader
(BioTek,
Winooski, VT). The data was normalized to protein
content of each sample measured with PierceTM BCA
protein assay kit (Thermo Fisher Scientific, Waltham,
MA) and reported as OD per µg of protein.

Caspase-3 assay
Caspase 3 levels were determined with
Apo-ONE® Homogeneous Caspase-3/7 Assay kit
(Promega, Madison, WI). MM1.S cells were plated in
24 well plates at 4 × 105 per well in CM and either left
untreated or treated with VLA-4-TC-NM RaST,
VLA-4-TC-NM alone, and [18F]FDG alone for 72 h as
described in the in vitro RaST section. Each condition
was tested in triplicate. At the end of treatment, the
CM was replaced with 250 µL PBS and 250 µL ApoONE® Homogeneous Caspase-3/7 reagent rhodamine
110,
(bis-(N-CBZ-L-aspartyl-L-glutamyl-L-valyl-Laspartic acid amide; Z-DEVD-R110) was added to the
wells. The intracellular active Caspase 3/7 removed
the DEVD peptides and released the strongly
fluorescent R110, which was then excited at 499 nm,
and the resulting fluorescence was detected at 521 nm
with a Synergy/NEO2 multi-mode reader (BioTek,
Winooski, VT). Fluorescence intensities from
VLA-4-TC-NM RaST, VLA-4-TC-NM alone, and
[18F]FDG alone were compared to the fluorescence
intensity obtained from the untreated cells and
expressed as a ratio over the untreated cells.

Flow cytometry
DNA fragmentation, such as double-strand
breaks, and the associated upregulation of the DNA
repair mechanisms is one of the downstream effects of
intracellular oxidative stress damage. The degree of
DNA repair process was assessed by measuring the
level of γH2AX, a phosphorylated histone variant
[71]. MM1.S cells were treated with VLA-4-TC-NM
RaST, VLA-4-TC-NM, [18F]FDG or left untreated for
72 h as described in the in vitro RaST section. At the
end of the incubation period, the cells were
mechanically harvested, and washed three times with
FACS buffer (PBS supplemented with 0.1% FBS).
After the cells were permeabilized with BD
Phosflow™ Perm III buffer (BD Biosciences, San Jose,
CA), the staining was performed with mouse
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anti-human γH2AX PE-pS139, clone N1-431 (BD
Biosciences, San Jose, CA), 0.5 µg/106 cells for 60 min
at 4 °C. Concurrently, the cell cycle phases of cells that
have undergone treatment and the controls were
determined with the 4′,6-diamidino-2-phenylindole
stain (DAPI, BD Biosciences, San Jose, CA) at 8 µg/106
cells. The dead cells were identified and quantified
using the membrane-impermeable dye Propidium
iodide staining solution (PI, BD Biosciences, San Jose,
CA). The expression levels of CD49d, CD61, CD71,
and GLUT1 were determined using the following
antibodies: PE mouse anti-human CD49d clone 9F10,
FITC mouse anti-human CD51/CD61 clone 23C6, PE
mouse anti-human CD71 clone M-A712, Alexa Fluor
647 mouse anti-human GLUT1 (all from BD
Biosciences, San Jose, CA). The stained cells were
analyzed with the Gallios flow cytometer (Beckman
Coulter Life Sciences, Brea, CA) and the resulting data
were quantified with FlowJo software (Ashland, OR).

Ferroptosis inhibition with Ferrostatin-1
Ferroptosis inhibitor 3-amino-4-(cyclohexylamino)-benzoic acid, ethyl ester (FST-1, Cayman
Chemical, Ann Arbor, MI) was used to investigate the
involvement of Ferroptosis in RaST-mediated cell
death. MM1.S were plated and either left untreated or
treated with VLA-4-TC-NM RaST, as well as VLA-4
and FDG controls, as described in the in vitro RaST
section. FST-1 (10 µM) was added concomitantly with
the VLA-4-TC-NM RaST treatment. After 72 h
incubation at 37 °C/5% CO2 humidified atmosphere,
the CM was carefully removed from each well and
replaced with 0.5 mL of PBS containing 50 µL
tetrazolium compound (CellTiter 96® Aqueous One
Solution Cell Proliferation Reagent, Promega,
Madison, WI) to determine the percentage of live
cells. The plates were incubated at 37 °C for 1-4 h to
allow the tetrazolium compound to develop. The
resulting absorbance was detected at 490 nm with a
Synergy/NEO2
multi-mode
reader
(BioTek,
Winooski, VT).

Western immunoblot assay
MM1.S cells were treated with VLA-4-TC-NM
RaST, VLA-4-TC-NM, [18F]FDG or left untreated for
72 h as described in the in vitro RaST section.
Following treatment, the cells were mechanically
dissociated from 24-well plates using rubber-tipped
cell scrapers (Sarstedt, Newton, NC) and washed 3
times with PBS. Cells were then incubated with 25
mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1%
sodium deoxycholate, 0.1% SDS buffer (RIPA lysis
buffer, Abcam, Cambridge, MA) supplemented with
EDTA-free protease inhibitor cocktail (Pierce,
ThermoFisher, Waltham, MA) for 60 min at 4 °C
http://www.thno.org
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followed by centrifugation at 12,000 x g for 10 min.
Protein content was quantified using the BCA protein
assay (Pierce, ThermoFisher Scientific, Waltham,
MA). Lysates (50 µg total protein) were denatured for
5 min at 100 °C and proteins were separated by
sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) at 100 V for 1.5 h using
Mini-PROTEAN
TG
precast
gels
with
Tris/Glycine/SDS buffer system (BioRad, Hercules,
CA). The proteins were transferred to a
polyvinylidene fluoride membrane at 50 V for 2 h
(PVDF, Millipore, Burlington, MA). After blocking for
1 h in TBST blocking buffer (10 mM Tris-HCl, 150 mM
NaCl, and 0.05% [v/v] Tween-20, pH 7.5, 5% (w/v)
non-fat milk), the PVDF membrane was rinsed once
with TBST and incubated overnight at 4 °C with 1°
antibody diluted in TBST blocking buffer. After two
washes, 5 min each, the membrane was incubated
with 2° antibodies conjugated with horseradish
peroxidase (HRP) for 1 h at room temperature. The
unbound secondary antibody was removed with 3
washes in TBST, 10 min each. Bound 2° antibodies
were detected using SuperSignalTM West Pico Plus
Detection Substrate (Thermo Fischer Scientific,
Waltham, MA) and ChemiDocTM Imager (BioRad,
Hercules, CA). The following 1° antibodies were used
for immunoblotting: CD61 (1:1000, unconjugated,
clone SJ19-09, Novus Biologicals, Centennial, CO);
GLUT1 (1:1000, unconjugated, clone D3J3A, Cell
Signaling Technology, Danvers, MA); Bak (1:1000,
unconjugated, #3814, Cell Signaling Technology,
Danvers, MA); Bax (1:1000, unconjugated, #2772, Cell
Signaling Technology, Danvers, MA); p53 (1: 1000,
unconjugated, clone 1C12, Cell Signaling Technology,
Danvers, MA); Bcl-2 (1:1000, unconjugated, clone
D17C4, Cell Signaling Technology, Danvers, MA);
α-actin (1:1000, unconjugated, #4967, Cell Signaling
Technology, Danvers, MA). The following 2°
antibodies were used for immunoblotting: anti-rabbit
IgG-HRP (1:10000, conjugated to HRP, sc-2357, Santa
Cruz Biotechnology, Dallas, TX).

Mass Spectrometry-based Label-free Protein
Quantification
The
MM1.S
cells were
treated
with
VLA-4-TC-NM RaST or left untreated as stated in the
in vitro RaST section. Each condition was performed
in triplicate. At the end of treatment, the cells were
mechanically harvested with a rubber-tipped cell
scraper (Sarstedt, Newton, NC) and washed twice
with PBS. Samples were subjected to reduction for 10
min (10 mM TCEP/50 mM ammonium bicarbonate
pH 8/100 µL) and alkylation for 30 min (25 mM
Iodoacetamide), both at room temperature, followed
by digestion with 0.5 µg trypsin (SOLu-Trypsin
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Dimethylated, Sigma) at 37 °C overnight. The digest
was acidified to the final 1% TFA before cleaning up
with Pierce C18 tip (Thermo Fisher Scientific, San
Jose, CA) following the vendor’s instruction. The
extracted peptides were dried and resuspended prior
to LC-MS/MS analysis.
LC-MS/MS analysis was carried out on an
Orbitrap Fusion Lumos (Thermo Fisher Scientific, San
Jose, CA) mass spectrometer coupled with a U3000
RSLCnano HPLC (Thermo Fisher Scientific, San Jose,
CA). The peptide separation was carried out on a 75
µm × 50 cm PepMap C18 column (Thermo Fisher
Scientific, San Jose, CA) at a flow rate of 0.3 μL/min
and the following gradient: time = 0-4 min, 2% B
isocratic; 4-8 min, 2-10% B; 8-83 min, 10-25% B; 83-97
min, 25-50% B; 97-105 min, 50-98% B. Mobile phase
consisted of A: 0.1% formic acid; mobile phase B: 0.1%
formic acid in acetonitrile. The instrument was
operated in the data-dependent acquisition mode in
which each MS1 scan was followed by higher-energy
collisional dissociation (HCD) of as many precursor
ions in 2-second cycle (Top Speed method). The mass
range for the MS1 was done using the FTMS was 365
to 1800 m/z with resolving power set to 60,000 at 400
m/z and the automatic gain control (AGC) target set
to 1,000,000 ions with a maximum fill time of 100 ms.
The selected precursors were fragmented in the ion
trap using an isolation window of 1.5 m/z, an AGC
target value of 10,000 ions, a maximum fill time of 100
ms, a normalized collision energy of 35 ms, and an
activation time of 30 ms. Dynamic exclusion was
performed with a repeat count of 1, exclusion
duration of 30 s, and a minimum MS ion count for
triggering MS/MS set to 5000 counts.
Sequence mapping and label-free quantification
were done using Proteome Discoverer (version PD
2.3). Database searches were established against the
Human reference proteome (Uniprot.org) with the
Byonic search engine launched by PD. The digestion
enzyme was trypsin. Oxidation of methionine and
acetylation of N-terminal of protein were specified as
variable modifications. Protein quantification was
achieved by using total intensities of all precursors.
Pathways discoveries were performed using the
Kyoto Encyclopedia of Genes and Genomes (KEGG),
the WiKiPathways database, and the REACTOME
Pathway database.

Histology
Femurs from treated and control animals were
excised at predetermined time points and
immediately placed in 10% neutral buffered formalin
solution (VWR, West Chester, PA), where they
remained for 48 h. The femurs were rinsed six times
with PBS for 15 min each and decalcified with 14%
http://www.thno.org
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EDTA for two weeks. After decalcification, the femurs
were rinsed six times with PBS for 15 min each. The
femurs were hydrated consecutively with 30%, 50%,
and 70% alcohol for 15 min each. The femurs were
embedded in paraffin, and 5 µm sections were
obtained. The sections were stained with
Hematoxylin/Eosin (H&E) and the Tartrate Resistant
Acid Phosphatase (TRAP) stains by the Washington
University Musculoskeletal Research Core. The
stained sections were imaged with the Zeiss Axio
Scan.Z1 (Zeiss-USA, San Diego, CA), and the images
were analyzed with the ZEN 2.3 software (Zeiss-USA,
San Diego, CA). Positive TRAP stain cells from the
entire section were counted and presented as OC per
section.

Animal models
All animal experiments were conducted in
compliance with Washington University School of
Medicine (WUSM) Institutional Animal Care and Use
Committee (IACUC) guidelines and the Guide for the
Care and Use of Laboratory Animals. Female Fox
Chase SCID beige mice (5-6 weeks old) were obtained
from Charles River Laboratory (Wilmington, MA).
C57BL/6-KaLwRij mice predisposed to MM [72, 73]
were obtained from Dr. Greg Mundy (OsteoScreen,
Inc., San Antonio, TX) and maintained at WUSM
animal facility. Animals purchased from vendors
were allowed to acclimate for 1 week prior to studies
and all animals were provided with food and water ad
libitum. When needed, euthanasia was performed by
cervical dislocation after anesthesia with 5%
isoflurane (Pivetal®, DCM, WUSM). Prior to cell
implantation, each cell line was tested for the reporter
expression by performing in vitro BLI with 1 x 105 cells
plated in a black 96-well plate. MM1.S cells (1 x 106
per mouse in 100 µL saline) were injected
intravenously (tail vein) in Fox Chase SCID beige
mice for the xenograft MM model. 5TGM cells (1 x 106
per mouse in 100 µL saline) were injected
intravenously (tail vein) in C57BL/6-KaLwRij mice
for the isograft MM model. Tumor progression was
monitored by detection of live cells with BLI.

Bioluminescent imaging (BLI)
In vivo bioluminescence imaging of animals
bearing MM1.S/CBR/GFP and 5TGM/CBR/GFP
cells was performed on the days indicated with an
IVIS Lumina (PerkinElmer, Waltham, MA; Living
Image 3.2, 1-300 sec exposures, binning 2-8, FOV
12.5cm, f/stop 1, and open filter). Mice were injected
intraperitoneally with 150 mg/kg D-luciferin in PBS
(Gold Biotechnology, St. Louis, MO) and imaged 10
min later under isoflurane anesthesia (2%, vaporized
Total
photon
flux
(radiance,
in
O2).
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photons/sec/cm2/steradian) was measured from
fixed region of interest (ROI) over the entire ventral
side of the mice using Living Image 2.6. A precipitous
drop in photon flux was considered to be an
indication of defective circulation and the affected
animal was removed from the observation group.

In vivo RaST
In vivo RaST was performed in disseminated
xenograft and isograft models. Animals (n = 5 per
group) were systemically implanted with 1 × 106 of
either MM1.S/CBR/GFP (5-6 weeks old male Fox
Chase SCID beige mice) or 5TGM/CBR/GFP (5-6
weeks old male C57BL/6-KaLwRij mice) cells
through the tail vein. Six days after implantation,
tumor progression was determined using BLI
(baseline). Animals with a whole-body flux of about 1
x 106 were fasted for 16 h and treated with
αvß3-TC-NM + VLA-4-TC-NM RaST, αvß3-TC-NM
RaST, VLA-4-TC-NM RaST, or left untreated. Each
αvß3-TC-NM RaST and VLA-4-TC-NM RaST
treatment consisted of 50 µL NM (5 µg TC) mixed 1:1
with saline to minimize viscosity. The αvß3-TC-NM +
VLA-4-TC-NM RaST treatment consisted of 50 µL (5
µg TC) of each NM type mixed with 50 µL saline.
[18F]FDG (29.6 MBq/animal) was administered
intraperitoneally 60-90 min later. The therapy was
repeated once weekly for 5 weeks and monitored with
weekly BLI.

Data analysis and statistics
In vitro RaST experiments were repeated three
times with each condition performed in triplicate to
control for the intra-experimental variability. The
experiments were not randomized and the analysis
was not blind. Metabolomics and proteomics studies
were conducted using triplicate samples for each
condition. In vivo RaST sample sizes were determined
using previous experience [74]. Specifically, the
sample size would depend on the effect size as
defined by the mean difference between untreated
and treated groups. For example, two-sided t-test
would predict a sample size of n = 5 with 80% power
to detect an effect size of 2.1 with a type I error rate of
0.05. Quantification of OC in bone sections was
performed using both femurs from n = 5 animals per
condition. Data and statistical analyses were
performed using GraphPad Prism 9.0.1 (151)
(GraphPad Software, Inc., La Jolla, CA) and Microsoft
Excel. For data with two groups and one variable, a
two-tailed unpaired t-test was used. Data with one
variable and multiple groups were analyzed with a
one-way ANOVA and Tukey’s or Dunnett’s multiple
comparisons test to determine the adjusted P-value.
Data with two variables and multiple groups were
http://www.thno.org
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analyzed with a two-way ANOVA and Tukey's
multiple comparisons test to determine the adjusted
P-value.
The data were expressed as mean ± SD, unless
indicated otherwise. Differences at the 95%
confidence level (P < 0.05) were considered to be
statistically significant.

Results
Convergence of nontoxic doses of TC and
[18F]FDG in VLA-4 (MM) expressing cells
selectively inhibits tumor proliferation
Conjugation of drugs to biological carriers for
delivery to different cell types presents several
challenges, including modifying the drug’s intrinsic
properties, pharmacokinetics, and intracellular
distribution that could disrupt drug action. To
circumvent these hurdles, we loaded the same
amount of non-modified TC inside unilamellar
phospholipid NMs using the method we reported
previously [75]. A small-molecule peptidomimetic
(LLP2A) that targets activated VLA-4 [43] or a
quinolone molecule that has a high affinity for
activated αvß3 [49] were inserted onto the surface of
the NMs to obtain VLA-4-TC-NMs and αvß3-TC-
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NMs, respectively. Using the VLA-4-expressing
human myeloma cell line, MM1.S [65], we determined
the optimal non-therapeutic doses for both TC and
[18F]FDG to prevent intrinsic toxicity by the RaST
component at high doses. Treatment of MM1.S cells
with increasing amounts of VLA-4-TC-NMs resulted
in dose-dependent cell death after incubating for 24 h.
While 0.5 µg, 2.5 µg, and 5 µg TC killed about 25%,
25%, and 75% of the MM cells, respectively, treatment
with 0.1 µg TC produced no appreciable cell death
(Figure 2A). Similarly, [18F]FDG killed less than 20%
of the cells at <1 mCi after 24 h (Figure 2B). Based on
these results, we chose the lowest amount of TC (0.1
µg) and [18F]FDG (0.1 mCi) for subsequent in vitro
RaST studies.
A delayed cytotoxic effect of RaST was observed
at 72 h after treating MM1.S cells with the nontoxic
amounts of VLA-4-TC-NM and [18F]FDG (Figure 2C).
Using the 72 h time point, we demonstrated that the
response of MM1.S cells to VLA-4-TC-NM RaST
required the co-localization of both TC and [18F]FDG
to exert a sustainable cell-killing effect (Figure 2D). By
contrast,
RaST
was
ineffective
in
killing
RaST-resistant MM1.S cells which have low VLA-4
expression [43] or genetically modified VLA-4
knockout MM1.S cells [43] (Figure 2D). Taken

Figure 2. Non-lethal amounts of TC and [18F]FDG converge in target cells to induce cell death. (A) VLA-4 targeted NM loaded with 0.1 µg TC did not lead to cell
death; Quantitative data are shown as percent of live cells compared to the untreated cells. (B) [18F]FDG administered at 3.7 MBq-27.75 MBq (0.1 mCi-0.75 mCi) induce
moderate degree of cell death; (C) VLA-4-TC-NM RaST induced about 40% MM1.S cell death 72 h after treatment; statistical significance was determined using unpaired
two-tailed t-test and a 95% confidence level. The difference between 48 h and 72 h VLA-4-TC-NM RaST was significant (P = 0.0228). (D) VLA-4-TC-NM RaST-induced cell death
requires the expression of VLA-4 by MM1.S cells; MM1.S cells expressing VLA-4 (WT) were compared to VLA-4-TC-NM RaST-resistant MM1.S cells (NR) expressing low levels
of VLA-4 and VLA-4 knockout cells (CD49dKO). The data were analyzed with one-way ANOVA and Dunnett's multiple comparisons tests. Untreated versus RaST + WT: P <
0.0001; untreated versus VLA-4-TC-NM RaST + RaST-resistant (RaSTNR) cells: P = 0.0473.
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together, these data demonstrate a synergistic
interaction
between
nontoxic
doses
of
a
photosensitizer and a radionuclide capable of
emitting Cerenkov radiation to exert specific and
durable therapeutic effects on cancer cells.

VLA-4-TC-NM RaST increases ROS and
non-enzymatic lipid hydroperoxidation in
MM1.S cells
Overproduction of ROS leads to non-enzymatic
peroxidation of lipids in plasma and organelle
membranes with polyunsaturated fatty acids (PUFA),
such as linoleic acid, being primary targets [76]. The
downstream products of PUFA peroxidation, mostly
4-hydroxynonenol
(4-HNE),
malondialdehyde
(MDA), and acrolein, form irreversible protein
adducts, leading to prolonged oxidative stress and
consequent apoptosis [77]. While RaST is known to
induce ROS, its mechanism of action has not been
explored. We first quantified the ROS that RaST
produces by measuring the levels of hydroxyl and
peroxyl radicals in MM1.S cells with H2DCFDA
fluorogenic dye 72 h after treatment. We found that
RaST induced significantly higher amounts of ROS in
cells treated with VLA-4-TC-NM RaST compared to
untreated cells (P = 0.01) or the cells treated with
either VLA-4-TC-NM (P = 0.01) or [18F]FDG (P = 0.03)
(Figure 3A). The persistently elevated ROS levels
correlated with an increase in hydroperoxidized
lipids, which also increased to a lesser extent with
VLA-4-TC-NM alone (Figure 3B). Analysis of data
obtained from mass spectrometry identified 3β,5α,6βtrihydroxycholestane (triol), 7-ketocholesterol, and
malondialdehyde downstream effectors of lipid
hydroperoxidation (Figure 3C). Thus, we uncovered
with experimental evidence that the hydroperoxidized lipids profile points to a mechanism
where lipid hydroperoxidation is a critical upstream
event leading to MMC apoptosis of RaST treated cells.
The photophysical nature of the treatment via
cytotoxic ROS generation complements current
combination pharmacologic drugs that utilize other
mechanisms of action.

VLA-4-TC-NM RaST induces apoptosis and
DNA double-strand breaks
Enhancement of lipid-protein adducts directly
activates caspase-3, leading to apoptosis [78].
Therefore, we investigated the state of caspase-3
activation in VLA-4-TC-NM RaST-treated and
untreated MM1.S cells. Although [18F]FDG and
VLA-4-TC-NM increased caspase-3 levels up to twoand five-folds, respectively, RaST induced a ten-fold
higher level of the enzyme than the untreated control
72 h post-treatment (Figure 3D). The upregulation of
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caspase-3 is a reversible process that does not
necessarily culminate in apoptosis-mediated cell
death. Using the propidium iodide, we found a direct
correlation between activated caspase-3 and cell
death. VLA-4-TC-NM RaST mediated cell death was
significantly higher than either of the controls,
[18F]FDG (P = 0.01), and VLA-4-TC-NM (P = 0.04)
(Figure 3E).
Protein
adducts
resulting
from
hydroperoxidation of PUFA have been shown to
interfere with the DNA repair function of p53 [77, 79].
Therefore, we investigated the downstream effects of
p53 mediated DNA repair by measuring the levels of
γ-H2A histone family member X (γ-H2AX), a
precursor to DNA repair complex assembly and a
direct indicator of the DNA double-strand breaks
repair activity [71, 80]. Our result showed that
VLA-4-TC-NM RaST significantly increased the
γ-H2AX level compared to controls (Figure 3F). These
changes occurred predominantly in the S phase of cell
cycle (Figure 3F), suggesting that VLA-4-TC-NM
RaST interferes with the cells' ability to synthesize
DNA [81]. The ensemble of the functional data points
to a mechanism where VLA-4-TC-NM RaST initiates
lipid peroxidation that leads to apoptosis (Figure 4A)
at levels that are significantly higher than those
generated by either [18F]FDG or VLA-4-TC-NMs
alone.

VLA-4 RaST Upregulates intracellular
pro-Apoptotic mediators of cell death
Oxidative stress exerted on a cell induces a
number of pro- and anti-apoptotic events, including
the upregulation of p53, Bcl-2 antagonist/killer
(BAK), Bcl-2-associated X protein (BAX) and Bcl-2
proteins [82-84]. To investigate whether RaST
modulates the expression of these proteins, we treated
MM1.S cells by RaST, [18F]FDG or NMs alone for 72 h
and analyzed the data relative to the untreated
control. The individual proteins were then resolved
with an SDS-PAGE and identified by Western blotting
with appropriate antibodies. Our data showed that
RaST upregulated the expression of BAX, Bcl-2, and
p53, but not BAK (Figure 3G), suggesting that BAK
protein, which is generally associated with the Bcl-2
family of proteins [85], was not involved in RaST
mediated cell death (Figure 4A). These results
highlight a RaST-induced apoptosis mechanism in
MM1.S cells via BAK-independent Bcl-2/BAX axis.

Ferroptosis inhibitor abrogates RaST effect
Ferroptosis is a distinct form of programmed cell
death that emanates from iron-dependent lipid
peroxidation [86, 87]. Fenton reactions involving Fe2+
ions from the intracellular labile iron pools and
http://www.thno.org
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peroxides are major contributors to intracellular lipid
peroxidation
under
physiological
conditions.
Previous studies provided compelling evidence
regarding the biochemical similarities of Ti(IV) and
Fe(III) [88]. During RaST, TC produces Ti-centered
radicals that could induce ferroptosis. Therefore, we
used Ferrostatin-1 (FST1), an inhibitor of ferroptosis
[89, 90], to investigate the contribution of this cell
death mechanism to RaST. Whereas RaST inhibited
cancer proliferation by 50%, the addition of FST1
restored cell viability, providing evidence for the role
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of ferroptosis in RaST-mediated cell death (P = 0.01;
Figure 3H).

RaST upregulates pro-apoptotic and
downregulates pro-survival proteins
RaST has the potential to perturb multiple
pathways associated with cell death. To assess the
dynamic changes, we performed label-free MS
proteomics with lysates from MM1.S cells treated
with VLA4-TC-NM RaST and the untreated controls.
Using RaST cutoff ratios of ≥ 1.5 (upregulated) and ≤

Figure 3. Mechanism of VLA-4-TC-NM RaST. (A) VLA-4-TC-NM RaST generates significantly more ROS (P=0.0039) compared to either [18F]FDG (NS) or
VLA-4-TC-NM alone (NS) when compared to no treatment; 4 x 105 MM1.S cells were treated with [18F]FDG, VLA-4-TC-NM, VLA-4-TC RaST, or left untreated. ROS
measurements were performed 72 h later using H2DCFDA. (B) Hydroperoxydation of PUFA increased in cells treated with VLA-4-TC-NM RaST. MM1.S cells were plated and
treated as in (A). The level of PUFA hydroperoxidation was measured with a lipid peroxidation assay 72 h later. VLA-4-TC-NM and VLA-4-TC-NM RaST produced significantly
more lipid hydroperoxidation (P = 0.001 and P < 0.0001, respectively) than no treatment control. (C) VLA-4-TC-NM RaST-induced PUFA hydroperoxidation generated reactive
aldehydes 72 h after administration. The cells were treated with VLA-4-TC-NM RaST or left untreated. 3ß,5α,6ß-THC-triol, 7-ketocholesterol, and malondialdehyde levels were
significantly higher (P = 0.02, P = 0.02, P = 0.009, respectively) in treated cells; multiple t-tests were used for the statistical analysis. (D) Caspase-3 level was significantly higher
in cells treated with VLA-4-TC-NM RaST compared to [18F]FDG and VLA-4-TC-NM (P < 0.0001 and P = 0.003, respectively) after 72 h of treatment; one-way ANOVA and
Tukey's multiple comparisons tests were used for the statistical analysis. (E) Treatment of MM1.S cells with VLA-4-TC-NM RaST significantly increased the cell death
(VLA-4-TC-NM RaST versus untreated: P = 0.0003; VLA-4-TC-NM RaST versus [18F]FDG: P = 0.005; VLA-4-TC-NM RaST versus VLA-4-TC-NM: NS). The cells were treated
as in (A). After 72 h, the cells were treated with 0.1 µg PI, and the amount of cell-associated PI was determined with Flow Cytometry; one-way ANOVA and Tukey's multiple
comparisons tests were used for the statistical analysis. (F) dsDNA breaks were significantly more abundant 72 h after VLA-4-TC-NM RaST. The cells were treated as in (A).
After 72 h, the cells were stained with anti-γH2AX and DAPI. Flow Cytometry analysis showed an overall increase in dsDNA breaks during the S-phase. Specifically, dsDNA
breaks were significantly more frequent during VLA-4-TC-NM RaST treatment compared to VLA-4-TC-NM (P = 0.003), [18F]FDG (P = 0.0002), and the untreated cells (P <
0.0001); 2way ANOVA and Tukey's multiple comparisons tests were used for the statistical analysis. (G) Western blotting showed increased levels of apoptosis-related proteins
72 h after VLA-4-TC-NM RaST. The cells were treated as in (A). (H) Ferroptosis inhibitor Ferrostatin-1 significantly inhibited VLA-4-TC RaST mediated cell death (P = 0.015).
MM1.S cells were plated as in (C). Ferrostatin-1 was administered concomitantly with VLA-4-TC RaST and VLA-4 control at the final concentration of 10 µM. Three-way
ANOVA and Tukey’s multiple comparisons tests were used for statistical analyses.
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0.5 (downregulated) for the treated to untreated cell
lysate (RaST/NT), we identified 23 upregulated and 7
downregulated proteins (Figure 4B, Supplementary
Table 1). Among the upregulated proteins, we
identified IRF2BPL gene product (RaST/NT = 2.22)
and ribosomal protein S15 (RaST/NT = 4.08), which
are involved in the cellular response to genotoxic
stress through the p53 related mechanism.
Apolipoprotein A1 (RaST/NT = 2.31) is a component
of PUFA metabolism. In addition to p53 and PUFA
pathways, serine hydrolase dipeptidyl peptidase
(RaST/NT = 2.22) and nucleoporin POM121
(RaST/NT = 1.96) are implicated in apoptotic
pathways.
The
Ubiquitin-proteasome
system
components, Ubiquitin E2 (RaST/NT = 2.04) and 26S
(RaST/NT = 1.6), are involved in regulating
proteolysis. The upregulation of multicopper oxidase
enzyme F5 (RaST/NT = 1.8), responsible for
inhibiting lipid hydroperoxidation and Fenton
reaction, illustrates how MM1.S cells mount
countermeasures to inhibit the effects of cytotoxic
ROS in response to RaST generates. Beside
upregulating pro-apoptotic, RaST also downregulated
multiple pro-survival molecules such as those
involved in mRNA translation (ATXN2; RaST/NT =
1.6), protein-protein interactions (PDLIM3; (RaST/NT
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= 0.4), and fatty acid biosynthesis (OXSM; (RaST/NT
= 0.5).
Overall, these results point to the lipid
hydroperoxidation of PUFA by ROS as the event
proximal to RaST agents’ internalization. The
downstream events likely included the generation of
α,ß-aldehydes and protein adducts culminating in cell
death mediated by mitochondrial and caspasedependent mechanisms [91-93]. The combined
suppression of pro-tumor and upregulation of
antitumor proteins, as well as ferroptosis, enable RaST
to utilize multidimensional cell death mechanisms to
destroy cancer cells and overcome ROS-resistance
pathways cancer develop in response to treatment.

Respective expression of VLA-4 and αvß3 in
MM and OCs and GLUT1 in both cell types
enable orthogonal RaST
Interactions between MMC and OCs determine
extensive osteolysis and promote MMC proliferation
and resistance to antitumor immunity [94]. Inhibition
of OC activity with bisphosphonates such as
pamidronate and zoledronic acid relies on the high
affinity of these drugs for hydroxyapatite in the bone
matrix. Although combination therapies that include
bisphosphonates have improved skeletal health for

Figure 4. RaST induces multiple cell death pathways. (A) Proposed mechanisms of RaST-induced multidimensional cell death pathways. Red arrows are based on data
presented in this manuscript. (B) Ratios of relative abundances of proteins from either VLA4-TC-NM RaST treated cells or the untreated cells (RaST/NT). Red filled circles:
RaST/NT ≥ 1.5; green filled circles: RaST/NT ≤ 0.5. Triplicates of each experimental condition were analyzed.
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MM patients, toxicity of bisphosphonates, incomplete
blockade, or reduced availability of bone matrix to
bind bisphosphonates (due to osteoblast inhibition)
combine to mitigate their routine use in the clinic. The
newer and improved denosumab therapy [32] has
shown impressive results, with the drawback that
precursors can still differentiate once the antibody is
cleared. Instead of indiscriminately targeting skeletal
bone matrix or inhibiting the function of OCs with
different drugs, we explored a treatment paradigm
that
uses
the
same
drug
(TC)
and
radiopharmaceutical ([18F]FDG) RaST to deplete both
tumor-associated OCs and disrupt the MM-OC
interaction during therapy. This strategy requires
orthogonal delivery of TC to OC and MM cells. Unlike
metastatic breast cancer to the bone where αvß3 is
expressed in both cancer cells and OCs, we found that
MM1.S cells were positive for VLA-4 (CD49d), but not
αvß3 (CD61) (Figure 5A). Treatment of MM1.S with
VLA-4-TC-NM or combined treatment with VLA-4TC-NM and αvß3-TC-NM, followed by [18F]FDG
showed that the combination RaST was as effective as
the VLA-4 RaST alone (Figure 5B), demonstrating that
the low αvß3 expression prevents the contribution of
TC-loaded αvß3-targeted NM to RaST effect on
MM1.S cells in vitro.
Cells exist in 3D in vivo via cell-cell interactions
that require adhesion molecules. As exposure to the
BME can alter integrin expression [46], we determined
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if the target integrin expression on cancer cells and
OCs were retained. After establishing MM1.S in mice,
we isolated the bone marrow to measure CD61
expression by flow cytometry. Anti-human CD61
antibody, while efficiently staining the highly
ß3-expressing MDA-MB-231 breast cancer cells, was
negative for MM1.S, demonstrating that MM1.S
express low to no αvß3 in BME in vivo (Figure 5C).
This finding suggests that αvß3 targeting would be
largely ineffective on MM1.S in vivo. Expectedly, we
found that OCs isolated from murine bone marrow
expressed a significantly higher level of αvß3 in vitro
(Figure 5D), supporting the potential use of αvß3 to
target OC for orthogonal strategy. Selective delivery
of [18F]FDG to target cells requires the expression of
GLUT1 on both MM1.S and OCs and cancer cells.
Western blot shows that myeloma cell lines MM.1S
and 5TGM1 and, to a lesser extent, murine OCs
express GLUT1 (Figure 5D). Extension of in vitro RaST
to TC-loaded αvß3 NM in OCs showed a response
similar to the VLA-4-TC-NM RaST in MM1.S cells
(Figure 5E), indicating that under similar conditions,
both VLA-4 and αvß3 targeted NMs are capable of
delivering a sufficient amount of TC into their
respective target cells and the GLUT1 level is capable
of initiating RaST in both cell types. The differential
expression of the target biomarkers allowed us to
experimentally dissect the effects of combination
RaST on tumor and OC cell populations in vivo.

Figure 5. (A) CD49d and CD61 expression by MM1.S cells in culture; MM1.S cells were grown in culture with CM for 1-3 weeks prior to flow cytometry analysis. (B)
VLA-4-TC-NM RaST and VLA-4-TC-NM + αvß3-TC-NM RaST comparison in MM.S1 cells in vitro. (C) αvß3 expression by MM1.S cells in vivo compared to a control. Animals with
disseminated MM were euthanized 2-4 weeks after the inoculation and the bone marrow (BM) was examined with flow cytometry for αvß3 expression. MDA-MB-231 human
mammary adenocarcinoma cells grown in culture were used as a positive control. (D) αvß3 and GLUT1 expression by murine OCs. Bone marrow from femurs and tibias of 5
weeks old C57BL/6-KaLwRij male mice was harvested and differentiated to OCs as described in Shioi, et al. [68]. Proteins of interest detected with GLUT1 (clone D3J3A Rabbit
mAb) and αvß3 (clone SJ19-09) antibodies. (E), αvß3-TC-NM RaST in OC in vitro. OCs were differentiated from BMM for 7-14 days prior to the experiment. αvß3-TC-NM RaST
was performed as in (B). Averages of each dataset were compared to the untreated control using a one-way ANOVA and Tukey's multiple comparisons test.
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Figure 6. Dual cancer-osteoclast RaST in mice. (A) Fox Chase SCID beige MM1.S xenograft animals untreated or treated once weekly for five weeks with αvß3-TC-NM
RaST, VLA-4-TC-NM RaST, and αvβ3-TC-NM + VLA-4-TC-NM RaST; MM1.S/CBR/GFP cells (1 x 106 cells per animal) were implanted IV and the therapy was initiated after the
whole body radiance reached 1 x 106 photons/sec/cm2/steradian (p/s/cm2/sr). Tumor progression was monitored with weekly BLI. αvβ3-TC-NM + VLA-4-TC-NM RaST
significantly reduced tumor progression compared to no treatment (P = 0.0007). (B) Representative bioluminescence images of Fox Chase SCID beige MM1.S xenograft animals
treated with αvβ3-TC-NM + VLA-4-TC-NM RaST and the untreated controls. (C) C57BL/6-KaLwRij 5TGM isograft animals were implanted with 5TGM/CBR/GFP cells (1 x 106
cells per animal) and monitored as in (A). The test animals were untreated or treated once weekly for five weeks with αvβ3-TC-NM RaST, VLA-4-TC-NM RaST, and
αvβ3-TC-NM + VLA-4-TC-NM RaST. αvβ3-TC-NM + VLA-4-TC-NM RaST significantly inhibited tumor progression compared to no treatment (P = 0.0317). (D)
Representative bioluminescence images of C57BL/6-KaLwRij 5TGM isograft animals treated with αvβ3-TC-NM + VLA-4-TC-NM RaST and the untreated controls. Two-way
ANOVA and Tukey's multiple comparisons were used for the statistical analysis.

In vivo depletion of OCs potentiates MM
response to RaST via orthogonal cellular
VLA-4 and αvß3 targeting strategy
To demonstrate the application of the combined
therapy in vivo, we used two animal models of MM. A
previous study showed that RaST was able to inhibit
MM1.S proliferation and improved survival in an
immunocompromised model, although the tumors
relapsed due to minimal residual disease that did not
respond to treatment [43]. In this study, we assessed
whether the inactivation of OCs would enhance RaST
effect. MM1.S/CBR/GFP cells were injected
intravenously into Fox Chase SCID beige mouse
strain. The animals were monitored with BLI to detect
the appearance of skeletal tumor lesions. We initiated
treatments when the total photon flux from the
tumors reached 1 × 106 and continued once weekly for
five weeks. The animals were imaged once a week
and the total photon flux representing the viable
MM1.S cells was recorded. Data analysis showed that
VLA-4-TC-NM RaST alone produced initial tumor
inhibition, which was followed by an increase in
tumor growth (Figure 6A, B) similar to what was

reported previously [43]. Surprisingly, αvß3-TC-NM
RaST also suppressed tumor growth compared to the
untreated control, with P = 0.006. Given that MM1.S
cells do not express αvß3, our result provides new
evidence that depletion of OC could disrupt MM-OC
interactions or communication networks involved in
promoting MMC survival [17, 19, 52]. The unique
advantage of the orthogonal multicellular over
monocellular therapies was evident with the
combination αvß3-TC-NM + VLA-4-TC-NM RaST,
resulting in unprecedented progression-free survival
(P = 0.0007) for this MM model.
Next, we evaluated if the bimodal RaST will
improve
MM
treatment
response
in
an
immunocompetent syngeneic murine model for MM
by inoculating 5TGM1/CBR/GFP (1 x 106 per mouse)
cells in C57BL/6-KaLwRij mice [95]. All animals were
monitored with BLI and treated as described above.
Whereas mice treated with αvß3-TC-NM RaST or
VLA-4-TC-NM RaST alone did not exhibit statistically
significant tumor response compared to the untreated
animals,
the
combination
αvß3-TC-NM
+
VLA-4-TC-NM RaST significantly inhibited tumor
growth (Figure 6C, D). Surprisingly, enhanced tumor
http://www.thno.org
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proliferation was observed in the VLA-4-TC-NM
RaST only mice after day 28 (Figure 6C). As
previously reported, immune (T and NK) cells, which
are absent in Fox Chase SCID beige, have high VLA-4
expression [96, 97]. A likely scenario is that VLA-4
NM distributed TC to MM and immune cells,
depending on the relative expression levels of the
targeted biomarker. Under this condition, the net
amount of TC available to RaST is below the threshold
required to exert a therapeutic effect. Consistent with
this observation, the correlative increase, albeit
gradual, of tumor growth in the combination therapy
group could be attributed to the diminishing effect of
VLA-4 delivered TC in MMC. Similarly, immune cells
also express αvß3 [98], which can account for the
moderate initial response in the αvß3-TC-NM RaST
treated mice before following the trajectory of the
untreated mice. Regardless of the relatively poor
response using the single RaST approach, the
sustainable αvß3-TC-NM + VLA-4-TC-NM RaST
response suggests that targeting cancer and multiple
cells in BME could have a synergistic effect in cancer
therapy.
These data point to a strategy wherein sufficient
doses of TC could be delivered locally in the bone to
MM, OC, and select immune cells for RaST-mediated
simultaneous depletion to achieve complete treatment
response. The impressive result from combination
RaST in immunocompetent mice suggests that using
targetable biomarkers that activate antitumor immune
cells could improve progression-free survival in
immunocompetent mouse models. As novel
combination drug therapies are in high demand for
MM, RaST elicits diverse cell death pathways that will
complete the standard of care MM therapies.
An important assumption in this study is that
αvß3-TC-NM RaST will deplete OCs in vivo.
Therefore, we investigated the status of these cells in
RaST-treated mice with tartrate-resistant acid
phosphatase (TRAP), which is widely used as an
accurate marker of OC function and population in vivo
[58, 99, 100]. The relative abundance of OC was
assessed by quantifying TRAP-positive cells in the
bones of untreated and RaST treated (αvß3, VLA-4, or
αvß3 + VLA-4 TC loaded NMs) mice using either the
MM1.S or 5TGM models as described above. RaST
was administered three times, followed by harvesting
of femurs for TRAP immunohistochemistry.
TRAP-stained OCs were visible on the bone surface of
untreated mice (Figure 7A,B). Analysis of
TRAP-positive cells revealed that αvß3-TC-NM and
αvß3-TC-NM + VLA-4-TC-NM RaSTs were equally
effective in eliminating OC in vivo in the MM1.S
xenograft (Figure 7A) and 5TGM isograft (Figure 7B)
models, as revealed by the reduced or discontinuous
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TRAP-stain. Quantification of the data showed that
5TGM MM exhibited about a 3-fold decrease in OC
relative to controls (Figure 7D), but a marginal
reduction in the OC population was observed for
VLA-4-TC-NM RaST. A similar trend was found in
the immunocompromised mouse model, with about a
two-fold decrease of OCs in αvß3-TC-NM RaST from
control (Figure 7C). Expectedly, the combination
αvß3-TC-NM + VLA-4-TC-NM RaST exhibited a
similar profile as αvß3-TC-NM RaST alone. These
observations confirm that αvß3-TC-NM RaST is
primarily responsible for inhibiting osteoclastogenesis
and combines with VLA-4-TC-NM RaST to potentiate
MM treatment response.

Discussion
Traditional
combination
chemotherapies
typically use two or more pharmacologic agents to
sustain therapeutic effects in cancer cells [101], but
these drugs also introduce cumulative side effects.
Particularly, MM is a fatal malignancy that requires a
multidrug therapeutic regimen to overcome
non-responsiveness and resistance. However,
end-organ damage, age, and co-morbidities render
MM patients fragile, further preventing aggressive
treatments due to off-target toxicities. To minimize
systemic and organ toxicities, we pioneered a unique
treatment paradigm, RaST, which is based on the
orthogonal delivery of individually nontoxic amounts
of a light-sensitive drug and a radiopharmaceutical to
cancer cells where they converge to produce toxic
amounts of ROS [42, 43]. RaST has the unique
advantage of using a photophysical ROS-generating
mechanism to eradicate target cells, regardless of their
origin. This scenario allowed us to use a single
photosensitizer (TC) instead of multiple drugs for
simultaneous MM-stromal cell therapy. Our data
highlights multiple cell death pathways involved in
TC-mediated RaST. First, RaST stimulates lipid
hydroperoxidation of PUFA [77, 102-105], a process
that produces various α,ß-aldehydes known to form
irreversible function-perturbing protein adducts and
culminates in caspase-3 independent apoptosis
induction (Figure 4A). Second, RaST also utilizes a
caspase-3 dependent apoptosis pathway via
Bax-independent Bak/Bcl-2 axis. Both of these
apoptosis-mediated cell death pathways emanate
from ROS generation. Third, VLA-4-TC NMs induce
double-stranded DNA breaks by a ROS-independent
pathway [106] that relies on stable titanium-centered
radicals to produce DNA damage [42]. While this
mechanism may have limited contribution to cell
death due to the small doses used, it reveals another
path that could create a multidimensional
combination therapy that uses TC as both a
http://www.thno.org
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Figure 7. αvß3-TC-NM RaST leads to OC depletion. (A) OCs in femurs of Fox Chase SCID beige MM1.S xenograft and B, C57BL/6-KaLwRij 5TGM isograft treated with
indicated RaST and visualized with TRAP immunohistochemical stain. OC content in (C), Fox Chase SCID beige MM1.S xenograft and (D), C57BL/6-KaLwRij 5TGM isograft was
quantified as the total number of TRAP-positive cells per section using Zeiss ZEN 2.3 software. In both models, αvß3-TC-NM RaST, either alone or in combination with
VLA-4-TC-NM, significantly reduced the OC population (Fox Chase SCID beige MM1.S xenograft: P = 0.0005 and P = 0.0006, respectively; C57BL/6-KaLwRij 5TGM isograft: P
< 0.0001 and P < 0.0001, respectively). Two-way ANOVA and Tukey's multiple comparisons were used for statistical analysis.

photosensitizer and a pharmacologic drug at higher
doses. Finally, the surprising observation of
ferroptosis as a contributor to RaST-mediated cell
death points to a mechanism in which the biochemical
similarity of iron and titanium ions [88] enhance the
Fenton reaction during TC-mediated RaST. Based on
the above processes, the observed delay in the
effective killing of MM cells following RaST was not
surprising as these cell death pathways are not
instantaneous. During this progressive cell death
process, it is possible to amplify the treatment
response by adding specific pharmacological drugs
that leverage any of the above pathways to minimize
residual disease.
Our study reveals the effectiveness of
orthogonally targeting RaST against cancer cells and
their microenvironment in both immunocompetent
and immunocompromised MM mouse models. While

VLA-4 RaST primarily accounted for anti-myeloma
activity in vitro, both αvß3 and VLA-4 RaST
individually exerted a therapeutic effect on MM in
both models. The data illustrates how disruption of
cancer-bone cell communication network alone using
the non-MM targeting αvß3-TC-NM could inhibit
cancer proliferation. Other studies have shown that
treatment of MM with the anti-resorptive bone agent,
zoledronic acid [107], and the Receptor Activator of
NF-kB ligand (RANKL) inhibitor, denosumab [32]
reduced osteolysis and inhibited MM progression
[108].
Unfortunately,
renal
clearance
of
bisphosphonates has often raised concerns for their
tolerability in MM [32], and rebound effects due to
activation of stalled OC precursors upon
discontinuation of denosumab are an emerging
weakness of antibody treatment [109]. Although our
single cell-targeted RaST does not have similar
http://www.thno.org
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limitations, all treated animals experienced MM
rebound after a latent period, similar to what is found
in standard therapies. Implementation of the MM-OC
combination RaST using αvß3-TC-NM + VLA-4-TCNM in vivo achieved prolonged progression-free
survival for these mice. These data provide evidence
that the dual targeting of cancer cells and their
microenvironment can reduce both osteolysis and
MM tumor burden in vivo by depleting OCs within
the tumor region.
We found stark differences in treatment
response between the immunocompetent and
immunocompromised MM models. Not only did
VLA-4 RaST have a negligible effect on tumor
progression compared to the untreated control, but
the tumor cells in treated mice also appeared to
proliferate at a faster rate than control in the
immunocompetent model. At the low dose of TC used
in this study, the presence of VLA-4 expressing
immune cells in this model could reduce the effective
dose of TC available for effective RaST in MM cells,
which was not the case in the immunocompromised
model. Similarly, the αvß3 RaST followed a similar
trajectory as the untreated control, albeit with low
tumor inhibition at the early stages. Histological
assessment of bone tissue in both mouse models
reveals that at basal levels, the OC population was
higher in C57BL/6-KaLwRij strain relative to the Fox
Chase SCID beige strain. Logically, this imposes a
higher threshold of OC depletion in the
immunocompetent model to achieve a therapeutic
effect, which accounts in part for the limited
inhibition effect on MM. The fact that the combination
of two apparently ineffective VLA-4 and αvß3 RaST
inhibited tumor growth in vivo supports a treatment
paradigm where the perturbation of communication
between cancer and multiple enabling cells can
synergize to exert durable tumor inhibition.
Collectively,
this
study
elucidates
the
multidimensional cell death mechanism that RaST
uses to exert a therapeutic effect. It also uncovers an
orthogonal
multicellular
treatment
paradigm
targeting
both
cancer
cells
and
their
microenvironment by activating the same drug type
to enhance cancer therapy. By using a photophysical
method to produce cytotoxic radicals in target cells,
the dual cell targeting RaST strategy can add a new
dimension to current combination therapies that only
use pharmacologic drugs. In particular, the latent
period between therapy initiation and the onset of cell
death (3 days) provides a therapeutic window when
cancer cells are most vulnerable to additional assaults.
This timing could be utilized to eradicate residual
disease before it transforms into a therapy-resistant
phenotype.
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